Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Lymphoma Academic Research Organisation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM. Patients treated with R-CHOP associated with an experimental drug ((polatuzumab, tazemetostat, venetoclax, entospletinib, lenalidomide, ibrutinib, anti PD1/anti PDL1 ….)
A short corticotherapy (prednisone, maximum 7 days) given during pre-phase therapy is allowed.
Eligible histological subtypes: in particular DLBCL NOS, PMBL, high grade B-cell lymphoma (HGBCL) withMYC and BCL2 and/or BCL6 rearrangements, HGBCL NOSFL grade 3B and untreated transformed low grade NHL.
≥ 18 years old, IPI = 0-5
With available tumor Biopsy (FFPE) that can be sent to RT3 platform at the time of inclusion (or the say after inclusion at the latest).
Patient that underwent needle core biopsy samples are not excluded if sufficient material is available for molecular and histopathological explorations
You may not be if
No available FFPE biopsy material or insufficient quality/quantity tumor samples according to prerequisite
No signed informed consent
Clareo Health | Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
